Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202006 | 0.86 | HTT (0.42) | HCAR1JAK2NPSR1KCNH2TP53 | |
| SCHEMBL16201997 | 0.86 | MAPK14 (0.40) | HCAR1KCNH2ALDH1A1LMNACYP3A4 | |
| SCHEMBL16201998 | 0.83 | KCNH2 (0.43) | HCAR1NPSR1KCNH2ALDH1A1LMNA | |
| SCHEMBL30725597 | 0.83 | KCNH2 (0.43) | HCAR1NPSR1KCNH2ALDH1A1LMNA | |
| SCHEMBL16202003 | 0.82 | HSD17B10 (0.42) | HCAR1NPSR1TP53ALDH1A1LMNA | |
| SCHEMBL31284563 | 0.79 | ALDH1A1 (0.49) | TP53ALDH1A1LMNACYP3A4MAPT | |
| SCHEMBL1956778 | 0.76 | ERN1 (0.40) | HCAR1NPSR1KCNH2ALDH1A1LMNA | |
| SCHEMBL16201996 | 0.74 | FLT3 (0.44) | HCAR1ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL16202009 | 0.74 | NOTUM (0.46) | NPSR1KCNH2MEN1KMT2A | |
| SCHEMBL12589923 | 0.74 | ALDH1A1 (0.53) | HCAR1JAK2NPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | SNX1, DPM1, SNU13 | HCAR1 1947/4885JAK2 4024/4885NPSR1 1862/4885 |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | DPM1, CROCC, SNX1 | HCAR1 1979/4885JAK2 4051/4885NPSR1 1877/4885 |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | HCAR1 1979/4885JAK2 4051/4885NPSR1 1877/4885 |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | HCAR1 2965/4885JAK2 3576/4885NPSR1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.